AcelRx appoints Jill Broadfoot as Class I director; board size set to ten

TALPHERA, INC.

Jill Broadfoot appointed to AcelRx board effective Nov 20, 2021; serves on Audit Committee.
Board size fixed at ten directors (4 Class I, 3 Class II, 3 Class III).
Broadfoot receives option for 30,000 shares at $0.7192 and 15,000 RSUs per director compensation policy.
Broadfoot is CFO of aTyr Pharma and formerly CFO of Vical, with audit and finance background.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jill M. Broadfoot

Class I Director

TLPH · TALPHERA, INC.

Effective: 2021-11-20
Filed: November 23, 2021, 6:59 PM ET

On November 20, 2021, the Board of Directors (the “Board”) of AcelRx Pharmaceuticals, Inc. (the “Company”) appointed Jill M. Broadfoot a Class I director of the Board, effective November 20, 2021, to serve until the expiration of her term at the 2024 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jill M. Broadfoot was appointed as Class I Director at TALPHERA, INC..

Action: appointed
Role: Class I Director

Exact text from the filing

On November 20, 2021, the Board of Directors (the “Board”) of AcelRx Pharmaceuticals, Inc. (the “Company”) appointed Jill M. Broadfoot a Class I director of the Board, effective November 20, 2021, to serve until the expiration of her term at the 2024 annual meeting of stockholders.

View on SEC.gov

TALPHERA, INC. filing history →

Source: SEC EDGAR

accession 0001437749-21-027323

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.